WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H510321
CAS#: 873697-71-3(free base)
Description: Omecamtiv mecarbil, also known as CK-1827452, is a cardiac specific myosin activator. It is clinically tested for its role in the treatment of left ventricular systolic heart failure. Omecamtiv Mecarbil specifically targets and activates myocardial ATPase and improves energy utilization. Omecamtiv Mecarbil improves systolic function by increasing the systolic ejection duration/stroke volume, without consuming more ATP energy, oxygen or altering intracellular calcium levels causing an overall improvement in cardiac efficiency. (source: http://en.wikipedia.org/wiki/Omecamtiv_mecarbil)
Hodoodo Cat#: H510321
Name: Omecamtiv mecarbil
CAS#: 873697-71-3(free base)
Chemical Formula: C20H24FN5O3
Exact Mass: 401.19
Molecular Weight: 401.442
Elemental Analysis: C, 59.84; H, 6.03; F, 4.73; N, 17.45; O, 11.96
Related CAS #: 1628699-20-6 (2HCl H2O) 873697-71-3(free base)
Synonym: Omecamtiv mecarbil; CK1827452; CK 1827452; CK1827452.
IUPAC/Chemical Name: methyl 4-(2-fluoro-3-(3-(6-methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate
InChi Key: RFUBTTPMWSKEIW-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
SMILES Code: O=C(N1CCN(CC2=CC=CC(NC(NC3=CC=C(C)N=C3)=O)=C2F)CC1)OC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 401.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Spinarova L, Spinar J. Pharmacotherapy of dilated cardiomyopathy. Curr Pharm Des. 2014;21(4):449-58. PubMed PMID: 25483945.
2: Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina. JACC Heart Fail. 2014 Nov 11. pii: S2213-1779(14)00379-5. doi: 10.1016/j.jchf.2014.07.009. [Epub ahead of print] PubMed PMID: 25453536.
3: McNeice AH, McAleavey NM, Menown IB. Advances in clinical cardiology. Adv Ther. 2014 Aug;31(8):837-60. doi: 10.1007/s12325-014-0141-9. Epub 2014 Jul 30. PubMed PMID: 25074280.
4: Wang Y, Ajtai K, Burghardt TP. Analytical comparison of natural and pharmaceutical ventricular myosin activators. Biochemistry. 2014 Aug 19;53(32):5298-306. doi: 10.1021/bi500730t. Epub 2014 Aug 7. PubMed PMID: 25068717; PubMed Central PMCID: PMC4139156.
5: Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Knöll R, Leite-Moreira AF, Lourenço AP, Mayr M, Thum T, Tocchetti CG. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014 May;16(5):494-508. doi: 10.1002/ejhf.62. Epub 2014 Mar 17. PubMed PMID: 24639064.
6: Shintani SA, Oyama K, Kobirumaki-Shimozawa F, Ohki T, Ishiwata S, Fukuda N. Sarcomere length nanometry in rat neonatal cardiomyocytes expressed with α-actinin-AcGFP in Z discs. J Gen Physiol. 2014 Apr;143(4):513-24. doi: 10.1085/jgp.201311118. Epub 2014 Mar 17. PubMed PMID: 24638993; PubMed Central PMCID: PMC3971663.
7: Valentova M, von Haehling S. An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013. Expert Opin Investig Drugs. 2014 Apr;23(4):573-8. doi: 10.1517/13543784.2014.881799. Epub 2014 Feb 4. Review. PubMed PMID: 24490905.
8: Pollesello P. Drug discovery and development for acute heart failure drugs: are expectations too high? Int J Cardiol. 2014 Mar 1;172(1):11-3. doi: 10.1016/j.ijcard.2013.12.136. Epub 2014 Jan 4. PubMed PMID: 24472177.
9: Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail. 2013 Jun;19(6):371-89. doi: 10.1016/j.cardfail.2013.04.002. Review. PubMed PMID: 23743486.
10: Zhang M, Mou T, Zhao Z, Peng C, Ma Y, Fang W, Zhang X. Synthesis and 18F-labeling of the analogues of Omecamtiv Mecarbil as a potential cardiac myosin imaging agent with PET. Nucl Med Biol. 2013 Jul;40(5):689-96. doi: 10.1016/j.nucmedbio.2013.02.013. Epub 2013 Apr 6. PubMed PMID: 23566883.
